ABSTRACT

Glioblastoma (GBM) is a lethal brain tumor containing a subpopulation of glioma stem cells (GSC). Pan-cancer analyses have revealed that stemness of cancer cells correlates positively with immunosuppressive pathways in many solid tumors, including GBM, prompting us to conduct a gain-of-function screen of epigenetic regulators that may influence GSC self-renewal and tumor immunity. The circadian regulator CLOCK emerged as a top hit in enhancing stem-cell self-renewal, which was amplified in about 5% of human GBM cases. CLOCK and its heterodimeric partner BMAL1 enhanced GSC self-renewal and triggered protumor immunity via transcriptional upregulation of OLFML3, a novel chemokine recruiting immune-suppressive microglia into the tumor microenvironment. In GBM models, CLOCK or OLFML3 depletion reduced intratumoral microglia density and extended overall survival. We conclude that the CLOCK–BMAL1 complex contributes to key GBM hallmarks of GSC maintenance and immunosuppression and, together with its downstream target OLFML3, represents new therapeutic targets for this disease.

SIGNIFICANCE:
Circadian regulator CLOCK drives GSC self-renewal and metabolism and promotes microglia infiltration through direct regulation of a novel microglia-attracting chemokine, OLFML3. CLOCK and/or OLFML3 may represent novel therapeutic targets for GBM.

INTRODUCTION

Glioblastoma (GBM) is the most aggressive and lethal form of adult brain cancer, for which current standard of care offers minimal clinical benefit (1). Extensive genomic profiling has identified key alterations of distinct signaling pathways in GBM, including the RTK–RAS–PI3K–PTEN, RB–CDKN2A, and TP53–ARF–MDM2 pathways (2–5). Efforts to target these altered signaling pathways, for example, EGFR or PI3K inhibition, have yielded minimal impact on outcomes of patients with GBM (6–9). Although these genetic alterations affect many intrinsic aspects of cancer cell biology, there is a growing recognition that these alterations also promote the expression of paracrine factors regulating the recruitment and activation of...
immune-suppressive cells in the tumor microenvironment (TME; refs. 10, 11). In GBM, for example, we demonstrated that PTEN deletion/mutation can drive expression of lysyl oxidase (LOX), which promotes infiltration of immune-suppressive tumor-associated macrophages (TAM) that in turn provide growth factor support for glioma cell survival (12). Such studies highlight the opportunities of identifying genetic alterations in glioma cells that establish symbiotic cancer-host interactions including immune suppression mechanisms in the TME.

In addition to the above genetic alterations, dysregulation of epigenetic programs is also known to affect tumor biology on many levels (13–15). In particular, various epigenetic regulators have been shown to play critical roles in the maintenance of glioma stem cells (GSC; such as N6-mA, EZH2, and DAXX) and in the regulation of tumor immunity (such as histone deacetylases; refs. 16, 17). These regulatory factors gain added significance as GSCs are critical to both tumor maintenance and therapeutic resistance in GBM (16). Moreover, pan-cancer computational analyses have demonstrated a positive correlation between stemness and immune signatures (18). Together, these insights prompted us to conduct a gain-of-function screen of known epigenetic regulators that may dually enhance GSC self-renewal and promote an immune-suppressive TME.

In this screen, the circadian regulator CLOCK emerged as the top hit.

The circadian rhythm serves as an important regulatory system maintaining homeostasis in normal cells and tissues (19, 20) and has been shown to play a pivotal role in cancer-relevant processes such as cell proliferation and survival, DNA repair, metabolism, and inflammation (19–21). CLOCK and BMAL1 (also known as ARNTL) are two key transcription factors of the circadian machinery, which constitute a heterodimeric complex (22). This complex can activate the expression of the PER and CRY genes, which ultimately forms a negative feedback loop to inhibit the activity of the CLOCK–BMAL1 complex (22).

There is an increasing recognition that the impact of CLOCK and BMAL1 on cancer pathogenesis is highly context- and disease-dependent (21). For instance, CLOCK or BMAL1 provides tumor suppressor–like functions in prostate, breast, ovarian, and pancreatic cancers, but exhibits tumor-promoting roles in colorectal cancer and acute myeloid leukemia (21, 23). In GBM, CLOCK or BMAL1 is a tumor-promoting factor that regulates glioma-cell proliferation and migration via regulation of the NFκB pathway (24) and can support GSC function via regulation of anabolic metabolism (25).

Here, we elucidate a novel function for CLOCK in supporting an immune-suppressive TME via its upregulation of OLFML3, a novel and potent chemoattractant of immune-suppressive microglia. Clinicopathologic correlations in human GBM point to CLOCK and OLFML3 as potential therapeutic targets for GBM.

RESULTS

CLOCK Promotes GSC Self-Renewal and Is Amplified in Human GBM

Employing previously characterized human neural stem cells (hNSC; ref. 26), a gain-of-function screen revealed that 31 of 284 epigenetic regulators could enhance hNSC self-renewal activity (Fig. 1A). CLOCK exhibited the highest self-renewal activity which was comparable with the positive control myr-AKT, and CLOCK overexpression was confirmed by immunoblot analysis (Supplementary Fig. S1A). Examination of The Cancer Genome Atlas (TCGA) GBM datasets revealed that CLOCK, but not genes encoding other epigenetic factors, is amplified in approximately 5% of GBM cases (Fig. 1B; Supplementary Fig. S1B) and 2.8% of low-grade glioma cases (Fig. 1C). Furthermore, increased gene copy number correlated positively with increased CLOCK mRNA levels (Fig. 1D). To further confirm the relevance of CLOCK in promoting GSC self-renewal and maintenance, we conducted shRNA-mediated depletion studies in human GSCs having relatively high CLOCK expression, such as GSC20, GSC167, and GSC272 (Supplementary Fig. S1C). Constitutive CLOCK depletion was associated with impaired self-renewal of GSC20 and GSC167 (Supplementary Fig. S1D and S1E), and an inducible shRNA knockdown system, termed ishCLOCK, reduced self-renewal in GSC272 and GSC20 (Fig. 1E; Supplementary Fig. S1F and S1G). Finally, we conducted shRNA-mediated CLOCK depletion in mouse QPP7 GBM having relatively high CLOCK expression (Supplementary Fig. S1C), and found that CLOCK depletion impaired QPP7 self-renewal, which can be rescued by reexpression of shRNA-resistant CLOCK cDNA (Supplementary Fig. S1H).

CLOCK heterodimerizes with BMAL1 to form a transcription factor complex that regulates core circadian clock genes (22). Within the heterodimer, depletion of one partner induces degradation of the other component (27). Indeed, we found that shRNA-mediated depletion of BMAL1 reduced CLOCK expression (Fig. 1F) and impaired self-renewal activity of GSC20 and GSC272 (Fig. 1G). SR9009 is an agonist of the nuclear receptors REV–ERBs, which function as direct negative regulators of the CLOCK–BMAL1 complex (28). SR9009 treatment inhibited the self-renewal ability of GSC20 and GSC272 (Fig. 1H), reinforcing the role of CLOCK/BMAL1 in promotion of GSC self-renewal.

Figure 1. CLOCK is amplified in GBM and regulates GSC self-renewal. A, Soft-agar colony formation of hNSCs overexpressing indicated epigenetic genes. n = 3 biological replicates. B, Genomic alterations of CLOCK and other epigenetic regulators (CHD2, KMT5C, SSRP1, FBXL19, JMJD8, PCMT1, NAP1L2, JMJD7, and ACTR6) in TCGA GBM database (provisional dataset; n = 528). C, Genomic alteration frequency of CLOCK in TCGA GBM datasets, GBM-LGG merged dataset and LGG datasets. D, CLOCK copy number is significantly correlated with CLOCK mRNA expression in TCGA GBM patients (n = 508); *, high level of amplification; +, gain; Neutral, no change; −, homozygous deletion; **, P < 0.01; ***, P < 0.001. E, Conditional deletion of CLOCK suppresses GBM tumorsphere formation. Representative images (left) and quantification (right) of tumorspheres in GSC272 cells expressing ishCLOCK or ishControl. Scale bar, 100 μm. n = 3 biological replicates; ***, P < 0.001. F, Immunoblots for CLOCK and BMAL1 in cell lysates of GSC272 and GSC20 expressing shRNA control (shC) or BMAL1 shRNAs. G, BMAL1 depletion impairs GBM tumorsphere formation. Representative images (left) and quantification (right) of tumorspheres in GSC20 and GSC 272 expressing two independent BMAL1 shRNAs or shControl. Scale bar, 100 μm. n = 4 biological replicates; ***, P < 0.001. H, SR9009 treatment impairs GBM tumorsphere formation. Representative images (left) and quantification (right) of tumorspheres in GSC20 and GSC272 treated with SR9009 at indicated concentrations. Scale bar, 100 μm. n = 4 biological replicates; ***, P < 0.001.
To determine the molecular basis of CLOCK's support of GSC self-renewal, gene-expression profiling and Gene Set Enrichment Analysis (GSEA) were compared in GSC272 with ishCLOCK versus ishControl. The major pathways affected were related to metabolism, including fatty-acid (FA) metabolism and glycolysis (Supplementary Fig. S2A), which aligns well with previous work showing that FA and glucose metabolism play critical roles in the maintenance of GSC self-renewal (25). Specifically, CLOCK depletion resulted in reduced expression of key glycolysis and tricarboxylic acid enzymes such as PGM1, HK2, LDHA, ACO2, SUCLG2, OGDH, and CS as well as FA enzymes such as ACACA, HSD17B, RPP14, ACAT1, and HADH (with PGM1 and ACACA showing the most dramatic reduction; Supplementary Fig. S2B and S2C). Treatment with a PGM1 inhibitor (lithium) or ACACA inhibitor (CP-640186) significantly impaired GSC272 self-renewal, and CLOCK-induced upregulation of self-renewal in GSC17 was blocked by inhibition of PGM1 or ACACA (Supplementary Fig. S2D and S2E). These findings are consistent with previous reports establishing CLOCK as a major regulator of metabolic pathways shown to be critical in supporting GSC self-renewal (25).

**CLOCK Promotes Microglia Infiltration in GBM**

In addition to therapeutic resistance, high stemness of cancer cells has been shown to correlate positively with immunosuppressive pathways in 21 types of solid tumors, including GBM (18). Indeed, in CLOCK-depleted GSCs, GSEA revealed prominent representation of immune-suppressive signatures, including IFNα/β response, TNFα/NFκB signaling, and inflammatory response (Fig. 2A). These immune signatures prompted in silico immune-cell auditing of TCGA GBM datasets using validated gene set signatures for 18 types of immune cells (10, 29–31). Analysis of immune-cell signatures showed that high CLOCK expression correlated positively with increased microglia and, to a lesser extent, hematopoietic stem cells, and with decreased CD8+ activated T cells and dendritic cells; other immune-cell types were not significantly changed (Fig. 2B; Supplementary Fig. S3A). Correspondingly, using transwell migration assays, conditioned media (CM) from CLOCK shRNA knockdown GSC272, GSC20, U87, or QPP7 cells exhibited reduced microglia migration relative to CM from shRNA control cells (Fig. 2C; Supplementary Fig. S3B–S3D). Moreover, the impaired microglia migration in CLOCK shRNA knockdown QPP7 cells can be rescued by reexpression of shRNA-resistant CLOCK cDNA (Supplementary Fig. S3D). Similarly, CM from shBMAL1 GSC20 cells inhibited microglia migration compared with CM from shControl cells (Fig. 2D). Conversely, CM from hNSC and GSC17 with enforced CLOCK expression increased microglia migration relative to controls (Fig. 2E; Supplementary Fig. S3E and S3F).

Finally, in human GBM tissue microarrays (TMA), CLOCK and BMAL1 signals showed a strong positive correlation with expression of the microglia markers TIMM119 and CX3CR1 (Fig. 2F and G). Together, these findings point to a potential link between high CLOCK expression and infiltration of immune-suppressive microglia into the GBM TME.

**CLOCK-Regulated OLFML3 Promotes Microglia Migration**

To identify putative CLOCK-regulated secreted factors governing microglia recruitment, our microarray profiling data were intersected with a secreted protein database (32). Using a ≥4.0-fold change in expression, coupled with qRT-PCR validation, 11 genes tracked positively with CLOCK expression including OLFML3, POSTN, TPPI2, LGMN, ALDH9A1, MCCC1, COL11A1, LYNX1, TPPI, LIPA, and RBP4. OLFML3 showed the most dramatic decrease in ishCLOCK GSC272 cells (Fig. 3A and B). Gene Ontology Enrichment Analysis (GOEA) on the subontology of Biological Process in TCGA patients with GBM showed that OLFML3, LGMN, and LIPA, but not other factors, correlated with leukocyte migration and chemotaxis (Supplementary Fig. S4). Among these three genes, only OLFML3 was reduced by CLOCK depletion in GSC20 (Supplementary Fig. S3A). Moreover, TCGA GBM bioinformatics analysis demonstrated that the expression of OLFML3, LGMN, and LIPA correlated positively with microglia markers (CX3CR1 and TMEM119), with OLFML3 showing the most significant correlation prompting further in-depth analysis (Supplementary Fig. S5B). Further studies using immunoblotting demonstrated that shRNA-mediated depletion of CLOCK or BMAL1 reduced OLFML3 expression in several GSC models, including mouse QPP7 (Fig. 3C) and human GSC20 and GSC272 (Fig. 3D). CLOCK depletion–induced decrease of OLFML3 expression in QPP7 cells was rescued by reexpression of shRNA-resistant CLOCK cDNA (Supplementary Fig. 5C).

Using transwell migration assays, recombinant OLFML3-supplemented medium dramatically increased microglia migration in a dose-dependent manner, which was comparable with the activity of the prototypical microglial chemokine CCL2 (aka, MCP1; Fig. 3E). Conversely, CM from shRNA-mediated depletion of OLFML3 in GSC272 or U87 cells showed reduced microglia migration (Fig. 3F; Supplementary Fig. S5D and S5E). To assess whether CLOCK and BMAL1 directly regulate OLFML3 expression, chromatin immunoprecipitation (ChIP)-PCR assays were performed, showing that CLOCK and BMAL1 bound to the OLFML3 promoter and that this binding was...
CLOCK in Tumor Immunity

**A** Hallmark pathways: ishCLOCK vs. ishControl

- UV_RESPONSE_UP
- KRAS_SIGNALING_DN
- ADIPOGENESIS
- PROTEIN_SECRETION
- INFLAMMATORY_RESPONSE
- TNFA_SIGNALING_VIA_NFKB
- UNFOLDED_PROTEIN_RESPONSE
- INTERFERON_ALPHA_RESPONSE
- INTERFERON_GAMMA_RESPONSE

![Graph showing Hallmark pathways]

**B** Immune signatures in TCGA patients with GBM

![Graph showing immune signatures]

**C** Transwell migration assay with GSC272 CM

![Transwell migration assay images]

**D** Relative migration

![Relative migration graph]

**E** Relative migration

![Relative migration graph]

**F** Relationship between CLOCK/BMAL1 and immune cell types

![Scatter plots showing relationship between CLOCK/BMAL1 and immune cell types]

**G** Expression of CLOCK, BMAL1, CX3CR1, and TMEM119 in low and high expression groups

<table>
<thead>
<tr>
<th></th>
<th>CLOCK</th>
<th>BMAL1</th>
</tr>
</thead>
<tbody>
<tr>
<td>CX3CR1</td>
<td>R = 0.5285</td>
<td>R = 0.6798</td>
</tr>
<tr>
<td>P</td>
<td>0.0006</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>TMEM119</td>
<td>R = 0.3952</td>
<td>R = 0.5931</td>
</tr>
<tr>
<td>P</td>
<td>0.0094</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>
Figure 3. CLOCK-regulated OLFML3 promotes microglia migration. 

A, Heat map representation of the microarray data of ishControl and ishCLOCK GSC272 cells shows the most downregulated genes (exhibiting a ≥4-fold change) encoding secreted proteins following CLOCK depletion. Red and blue indicate higher and low expression, respectively. 

B, qRT-qPCR validation of downregulated genes as in A. n.s., not significant (P > 0.05). 

C, Immunoblots for CLOCK and OLFML3 in cell lysates of QPP7 GSCs expressing shRNA control (shC), CLOCK shRNAs, or BMAL1 shRNAs. 

D, Immunoblots for OLFML3 in cell lysates of GSC272 (left) and GSC20 (right) expressing shRNA control (shC) or BMAL1 shRNAs. 

E, Recombinant OLFML3 protein at indicated concentrations promotes HMC3 microglia migration in transwell assay, and is comparable with positive control CCL2 (10 nmol/L). Representative images (left) and quantification (right). Scale bars, 300 μm; n = 3 biological replicates; *, P < 0.05; **, P < 0.01; n.s., not significant (P > 0.05). 

F, OLFML3-depleted GSC272 CM impairs HMC3 microglia migration in transwell assay. Representative images (left), shRNA knockdown efficiency and quantification (right). Scale bars, 300 μm; n = 3 biological replicates; **, P < 0.001. 

G, ChIP-PCR shows that CLOCK and BMAL1 bind to OLFML3 promoter and that this binding was diminished following CLOCK depletion. n = 3 biological replicates; *, P < 0.05; **, P < 0.01; n.s., not significant (P > 0.05). 

H, Luciferase (Luc) reporter assay shows that mutations in OLFML3 promoter E-box sites reduce the transcriptional activity of CLOCK for OLFML3 n = 3 biological replicates; *, P < 0.05; **, P < 0.001.
reduced in CLOCK-depleted GSC272 cells (Fig. 3G). Moreover, luciferase reporter assays showed that CLOCK-induced transcriptional activity was abolished by E-box mutations in the OLFML3 promoter region (Fig. 3H). We conclude that OLFML3 is a novel CLOCK-regulated chemokine with potent microglia recruitment activity.

**CLOCK Depletion Inhibits GSC Self-Renewal and Intratumoral Microglia Infiltration and Extends Survival**

To further investigate the role of CLOCK in GBM tumor biology, we utilized the ishCLOCK system to inducibly deplete CLOCK in GSC272 and GSC20 tumors implanted into SCID mice, revealing that CLOCK depletion significantly extended survival (Fig. 4A and B; Supplementary Fig. S6A). Using the murine model CT2A, which was isolated from a carcinogen-induced glioma and possesses a GSC-like phenotype (33), depletion of CLOCK or BMAL1 resulted in a significant extension of survival in C57BL/6 mice (Fig. 4C and D). Similarly, pharmacologic inhibition of the CLOCK–BMAL1 complex extended the survival of C57BL/6 mice implanted with CT2A cells (Fig. 4E). On the histologic level, the stem-cell markers OLIG2 and nestin and the proliferation marker Ki-67 were dramatically reduced, whereas apoptosis was increased upon CLOCK depletion (Fig. 4F and G; Supplementary Fig. S6B and S6C). In addition, infiltrating microglia were profoundly reduced (10-fold) in the CLOCK-depleted tumors (Fig. 4H; Supplementary Fig. S6D). The microglial phenotype, which can be immune-stimulatory (M1) or immunosuppressive (M2; ref. 34), is strongly biased toward the M2 phenotype in both mouse and human GBM tumors (Supplementary Fig. S7A and S7B). M2 microglia were significantly reduced in CLOCK-depleted tumors (Supplementary Fig. S7C) and, conversely, the M2 signature correlated positively with high expression levels of CLOCK and BMAL1 in TCGA patients with GBM (Supplementary Fig. S7D and S7E). Because OLFML3 plays a prominent role in microglia migration, we also explored the impact of shRNA-mediated depletion of OLFML3 on GBM growth, and found that decreased OLFML3 in the GSC272 model significantly extended survival (Fig. 4I). Together, these *in vivo* results confirm the role of CLOCK in promoting GBM tumor maintenance, which correlates with CLOCK-induced enhancement of stemness, proliferation, and survival, as well as increased recruitment of microglia into the GBM TME.

**DISCUSSION**

In this study, we uncovered the role and underlying mechanisms of the core circadian regulators CLOCK and BMAL1 in GBM tumor maintenance via its regulation of GSC self-renewal and immunity. We identified OLFML3 as a novel and potent CLOCK-regulated microglia chemoattractant in GBM and demonstrated that OLFML3 depletion can increase survival. The key role of the CLOCK–BMAL1 complex in GBM tumor biology, particularly its regulation of specific metabolic and immunity genes such as OLFML3, illuminates potential therapeutic targets governing key cancer hallmarks of stemness and immune suppression.

Circadian rhythm regulators have been extensively studied in model organisms (35) and have been linked to the development of cancers including breast, lung, and colorectal cancers (36, 37). For example, depletion of CLOCK or BMAL1 has been shown to impact leukemia stem-cell proliferation and enhance myeloid differentiation in acute myeloid leukemia (23), as well as suppress glioma cell proliferation and migration (24). Moreover, pharmacologic activation of the circadian clock components REV-ERBs, which repress transcription of CLOCK and BMAL1, have been shown to impair the growth of multiple cancer types including GBM (28). Specifically, activation of REV-ERBs is selectively lethal to cancer cells by affecting oncogenic drivers (such as HRAS, BRAF, PIK3CA, and others), inducing apoptosis and inhibiting autophagy (28). In this study, we extend the actions of CLOCK in GBM as a promoter of GSC self-renewal, suppressor of antitumor immunity and, consistent with recent reports, regulator of fatty-acid metabolism and glycolysis (25).

A hallmark feature of the GBM TME is an abundance of infiltrating immune cells (38) wherein microglia are known to contribute to an immunosuppressive microenvironment and support GBM progression (39). Here, our findings of CLOCK-regulated microglia recruitment are consistent with previous observations that the immune system can be regulated by circadian components (40) and that dysregulation of the intrinsic circadian clock can alter inflammatory responses (41, 42). In addition, our work also aligns with previous tumor biology findings showing that CLOCK can influence T-cell infiltration in melanoma (43) and that BMAL1 deficiency in endothelial cells impairs the migration of leukocytes in mice (44). Moreover, our mechanistic work reinforces this intimate link by demonstrating the capacity of CLOCK to specifically and directly regulate the chemokine OLFML3, which in turn recruits microglia into the GBM TME.

OLFML3 belongs to the family of olfactomedin domain-containing proteins, which have important roles in tumorigenesis and embryonic patterning (45). Previous work has shown that OLFML3 is a proangiogenic factor in the TME, where it promotes endothelial cell migration and sprouting through activation of the canonical SMAD1/5/8 signaling pathway (45). Along similar lines, it would be useful to determine potential druggable molecular pathways in microglia that are activated by OLFML3, thus expanding therapeutic targets for GBM. Intriguingly, microglia are known to express OLFML3 (46), suggesting that following a CLOCK-directed program of microglia recruitment, microglia themselves could further increase the recruitment of additional microglia through their own secretion of OLFML3 in a feed-forward manner. TAMs play an important role in GBM tumor biology, prompting assessment of the therapeutic benefit of targeting TAMs in GBM. To date, however, CSF1R inhibitor BLZ945 treatment of mouse GBM models has failed to deplete TAMs and elicited transient antitumor responses (47, 48). Correspondingly, a phase II clinical trial with the CSF1R inhibitor PLX3397 has shown minimal activity in patients with recurrent GBM (49). The basis for these meager responses is not clear, although it is worth noting that 2 of 37 patients with GBM who experienced extended progression-free survival (49) had tumors of the mesenchymal subtype that typically harbors *PTEN* deficiency. Along these lines, our recent studies demonstrated that inhibition of macrophage recruitment by LOX inhibitor specifically impairs *PTEN*-deficient GBM progression, establishing a synthetic lethal interaction between *PTEN*-deficient
LOX-expressing glioma cells and SPP1-expressing TAMs which support glioma cell survival (12). Thus, with respect to CSF1R inhibitors, it is tempting to speculate that patients with PTEN-deficient GBM may be particularly susceptible to such agents targeting TAMs. Along similar lines, our discovery here of the CLOCK–OLFML3–microglia axis and the correlative studies in human GBM TMAs showing high CLOCK and abundant microglia encourages the design of clinical trials targeting OLFML3 in patients with high-CLOCK GBM. We believe that targeting CLOCK–BMAL1 downstream targets,
as opposed to CLOCK–BMAL1 directly, provides a superior therapeutic strategy given the likelihood of disturbed sleep cycles by targeting circadian regulators. Finally, microglia are well known to be immunosuppressive cells in the GBM TME and may therefore dampen immune checkpoint blockade activity (50); thus, it is tempting to speculate that combined inhibition of OLFML3 and immune checkpoint blockade may also prove beneficial for patients with GBM.

**METHODS**

**Cell Culture**

HMC3 microglia were cultured in Eagle’s Minimum Essential Medium. CT2A, U87, and 293T cell lines were cultured in DMEM. All cell lines were cultured in the indicated medium containing 10% FBS (Sigma) and 1:100 antibiotic-antimycotic (Gibco), and were purchased from the ATCC. p53DN-hNSCs were generated by our laboratory as described recently (26). Patient-derived GSCs were provided by Dr. Erik P. Sulman and Dr. Frederick F. Lang from the Brain Tumor Center (The University of Texas MD Anderson Cancer Center). Mouse 005 and QPP7 GSCs were provided by Dr. Samuel D. Rabkin (Massachusetts General Hospital, Harvard Medical School) and Dr. Jian Hu (The University of Texas MD Anderson Cancer Center). All GSCs and neural stem cells (NSC) were cultured in N2B27 medium (Millipore Corporation) containing 5% B27, 20 μg/mL EGF, and 20 ng/mL basic fibroblast growth factor. These GSCs and NSCs have been validated through fingerprinting by the MD Anderson Cell Line Core Facility. All cells were confirmed to be Mycoplasma-free, and maintained at 37°C and 5% CO₂. CM were collected from treated or untreated cells as indicated after culturing for 24 hours in FBS-free culture medium.

**Tumorsphere Formation Assay**

Soft-agar colony formation assay and tumorsphere formation were performed as described previously (51).

**Epigenetic Screen**

The open reading frame (ORF) lentiviral vectors in the Precision Lentivector collection were obtained from the Functional Genomics Facility at MD Anderson Cancer Center. In 96-well plates, we packaged 284 ORF lentiviruses (encoding known epigenetic factors) individually and infected with p53DN-hNSCs. Stable sublines were generated by blasticidin selection and then subjected to soft-agar colony formation assay.

**Plasmids, Viral Transfections, and Cloning**

shRNAs targeting human and mouse CLOCK, BMAL1, and OLFML3 in the pLKO.1 vector (Sigma) were used in this study. Lentiviral vectors (8 μg) were generated by transfecting 293T cells with the packaging vectors pPAK2 (4 μg) and pMD2.G (2 μg). Lentiviral particles were collected 48 and 72 hours after transfection of 293T cells, filtered through a 0.45-μm filter (Corning), and then used to treat cells in culture. After 48 hours, cells were selected by puromycin (2 μg/mL). The following human shRNA sequences (CLOCK: #74: TRCN0000181974 and #75: TRCN0000181975; BMAL1: #96: TRCN0000019096 and #98: TRCN000019098; and OLFML3: #1: TRCN000186745 and #3: TRCN000203502) and mouse shRNA sequences (Clock: #1:TRCN0000095686 and #2:TRCN0000036474; Bmal1: #54: TRCN0000095054 and #57: TRCN0000095057) were selected for further use following the validation. Doxycycline-inducible plasmids were generated by cloning the desired shRNA sequences (shCLOCK #75) into a pLKO.1 vector through the Gateway Cloning System (Thermo Fisher Scientific). Following transfection, cells were treated with doxycycline (2 μg/mL) for 48 hours to knock down CLOCK. For rescue experiments, CLOCK shRNA knockdown QPP7 cells were transfected with a human CLOCK construct that is resistant to CLOCK shRNAs (shCLOCK #1 and #2).

**Immunoblotting**

Immunoblotting was performed following standard protocol (12). Antibodies were purchased from the indicated companies, including antibodies against β-actin (Sigma, #A5385), vinculin (EMD Millipore, #05-386), CLOCK (Cell Signaling Technology, #5157S), BMAL1 (Cell Signaling Technology, #14020S), and OLFML3 (Invitrogen, #PA3-31581).

**IHC and Immunofluorescence**

IHC was performed as standard protocol. In brief, a pressure cooker (95°C for 30 minutes followed by 120°C for 10 seconds) was used for antigen retrieval using antigen unmasking solution (Vector Laboratories). Antibodies specific to CLOCK (Cell Signaling Technology, #5157S), BMAL1 (Cell Signaling Technology, #14020S), CX3CR1 (Invitrogen, #702321), TMEM119 (BioLegend, #853302), CD206 (R&D Systems, #AF2535), cleaved caspase-3 (Cell Signaling Technology, #9661S), OLG2 (Millipore, #AB1328), nestin (Millipore, #MAB5326), and Ki-67 (Thermo Fisher Scientific, #RM-9106-S1) were used in this study. The human and mouse tumor tissue sections were reviewed and scored by TMARKER software (52). Slides were scanned using Pannoramic 250 Flash III (3DHISTECH Ltd) and images were captured through Pannoramic Viewer software (3DHISTECH Ltd). The studies related to human specimens were approved by the MD Anderson Institutional Review Board under protocol #PA14-0420. Immunofluorescence was performed as described previously (12), and antibodies specific to CX3CR1 (Invitrogen, #702321) were used. Images were captured using a fluorescence microscope (Leica DMi8).

**Migration Assay**

Human microglia HMC3 cells (5 × 10⁴) were suspended in serum-free culture medium and seeded into 24-well Transwell inserts (8 μm). Medium with indicated factors or CM was added to the remaining receiver wells. After 24 hours, the migrated microglia were fixed and stained with crystal violet (0.05%, Sigma) and then counted as cells per field of view under microscope.

**ChIP-PCR and Luciferase Reporter Assay**

ChIP-PCR was performed using the standard protocol. Briefly, GSC272 cells were cross-linked using 1% paraformaldehyde (PFA; 10 minutes) and then reactions were quenched using glycine (5 minutes) at room temperature. Cells were lysed with ChIP lysis buffer for 30 minutes on ice. Chromatin fragmentation was performed using a Diagenode Bioruptor Pico sonicator (45 cycles, each with 30 seconds on and 30 seconds off). Solubilized chromatin was then incubated with a mixture of antibody [CLOCK (Abcam, #ab3517) or BMAL1 (Cell Signaling Technology, #14020S)] and Dynabeads (Life Technologies) overnight. Immunocomplexes were then washed with RIPA buffer three times, once with RIPA-500 and once with LiCl wash buffer. Elution and reverse cross-linking were performed in direct elution buffer containing proteinase K (20 mg/mL) at 65°C overnight. Eluted DNA was purified using AMPure beads (Beckman-Coulter), and then was used to perform qPCR. The OLFML3 primer was designed according to the E-box of human OLFML3 gene (−412 to −229 bp; forward: TGACCACCTGGGCGGATGTT; reverse: CAGCAAAAGGCCATCTCTGTT). To perform the luciferase reporter assay, the promoter region of human OLFML3 (−412 to −229 bp to ATG) was amplified by PCR and inserted into the BglII/HindIII sites of the pGL3 vector to generate the corresponding reporter constructs with or without point mutations in human OLFML3 E-box sites. The luciferase reporter assay was conducted by transfecting the reporter constructs, CLOCK expression vector, and Renilla luciferase vector into 293T cells. Cells were harvested after 24 hours of transfection and luciferase activities were measured.

**Quantitative Real-Time PCR**

Cells were pelleted and RNA was isolated with the RNeasy Mini Kit (Qiagen). RNA was reverse-transcribed into cDNA by following
the ABM cDNA Synthesis Kit. Quantitative real-time PCR (qRT-PCR) was performed using SYBR Green PCR Master Mix (Thermo Fisher Scientific) in a 7500 Fast Real-Time PCR Machine (Applied Biosystems). qRT-PCR primers are listed in Supplementary Table S1. The expression of each gene was normalized to that of GAPDH.

**Microarray Analysis**

RNA was isolated as described above with slight modifications. ish-Control and ishCLOCK GSC272 cells (n = 2 biological replicates) were first lysed with Buffer RLT, then purified with TRIzol Reagent (Life Technologies) and chloroform. The remaining steps of the RNAeasy Mini Kit were then followed. Microarray experiments were conducted by the MD Anderson Sequencing and Microarray Core Facility using the Clarion D Assay (Thermo Fisher Scientific). Microarray experiments were performed in duplicate. The raw data were processed and analyzed by GenePattern using Transcriptome Analysis Console. Genes that were differentially expressed between ishControl and ishCLOCK GSC272 were subjected to GSEA.

**Mice and Intracranial Xenograft Tumor Models**

Female ICR SCID mice (3–4 weeks age) were purchased from Taconic Biosciences. Mice were grouped by 5 animals in large plastic cages and were maintained under pathogen-free conditions. All animal experiments were performed with the approval of MD Anderson Cancer Center’s Institutional Animal Care and Use Committee. The intracranial xenograft tumor model in SCID mice was established as we described recently (26). The mice were bolted and intracranially implanted with cells at MD Anderson’s Brain Tumor Center Animal Core. Mice with neurologic deficits or moribund appearance were sacrificed, and the tumor tissues were harvested for histologic analysis. Following transcerebral perfusion with 4% PFA, brains were removed and fixed in formalin, and were processed for paraffin-embedded blocks.

**Human Samples**

Tissue microarrays containing 35 human GBM samples and 5 normal brain tissues were purchased from US Biomax (catalog no. GL806f).

**Computational Analysis of Human GBM Data**

For analysis of human GBM data, we downloaded the gene-expression and copy-number data of TCGA datasets or other available datasets from GlioVis: http://gliovis.bioinfo.cnio.es/ or eBioPortal: https://www.ebioportal.org/. The expression and correlation of interesting genes in GBM, and GOEA were analyzed using GlioVis.

**Statistical Analysis**

All statistical analyses were performed with Student t test and represented as mean ± SD unless noted otherwise. The analysis of GBM TCGA database and TAM IHC staining for the correlation between genes or proteins was performed using the Pearson Correlation test (GraphPad Prism 7). The analysis of survival data from the GBM TCGA database was performed using the Log-rank (Mantel-Cox) test (GraphPad Prism 7). The P values were designated as *, *P < 0.05; **, *P < 0.01; ***, *P < 0.001; and n.s., nonsignificant (*P > 0.05).

**Data and Software Availability**

The newly generated microarray data have been submitted to the Gene Expression Omnibus repository, and the accession number is GSE140409.

**Disclosure of Potential Conflicts of Interest**

Y.A. Wang is a consultant for Merck, the Department of Defense, and the Emerson Collective. R.A. DePinho is a co-founder, advisor, and director at Tvardi Therapeutics. No potential conflicts of interest were disclosed by the other authors.

**Authors’ Contributions**

**Conception and design:** P. Chen, W.-H. Hsu, Z. Tan, Y.A. Wang, R.A. DePinho

**Development of methodology:** P. Chen, W.-H. Hsu, Z. Tan, Y.A. Wang

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** P. Chen, W.-H. Hsu, A. Chang, Z. Lan, A. Zhou, F.F. Lang, Y.A. Wang, R.A. DePinho

**Analysis and interpretation of data (e.g., statistical analysis, bio-statistics, computational analysis):** P. Chen, W.-H. Hsu, A. Chang, Z. Zhou, Y.A. Wang

**Writing, review, and/or revision of the manuscript:** P. Chen, A. Chang, D.J. Spring, Y.A. Wang, R.A. DePinho

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** P. Chen, D.J. Spring, Y.A. Wang

**Study supervision:** P. Chen, Y.A. Wang, R.A. DePinho

**Acknowledgments**

This work was supported by the Cancer Research Institute Irvington Postdoctoral Fellowship (to P. Chen), the Harold C. and Mary L. Daily Endowment Fellowship (to P. Chen), the Caroline Ross Endowed Fellowship (to P. Chen), the Emerson Collective Award (to Y.A. Wang), NIH R01 CA231349 (to Y.A. Wang), the Clayton & Modesta William Cancer Research Fund (to R.A. DePinho), NIH P01 CA117969 (to R.A. DePinho), NIH R01 CA084628 (to R.A. DePinho), and the Burkhart III Distinguished University Chair in Cancer Research Endowment (to R.A. DePinho). The authors thank Dr. Michael D. Peoples for providing shRNAs, Dr. Erik P. Sullivan for providing human-derived GSCs, and Drs. Samuel D. Rabkin and Jian Hu for providing mouse GSCs.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 1, 2019; revised November 26, 2019; accepted January 6, 2020; published first January 9, 2020.

**REFERENCES**


CLOCK in Tumor Immunity


43. de Assis L, Kinker GS, Moraes MN, Markus RP, Fernandes PA, Castrucci AM. Expression of the circadian clock gene BMAL1 positively correlates with antitumor immunity and patient survival in metastatic melanoma. Front Oncol 2018;8:185.


Peiwen Chen, Wen-Hao Hsu, Andrew Chang, et al.

Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor Microenvironment

Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-19-0400

Supplementary Material
Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2020/01/09/2159-8290.CD-19-0400.DC1

Cited articles
This article cites 52 articles, 10 of which you can access for free at:
http://cancerdiscovery.aacrjournals.org/content/10/3/371.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://cancerdiscovery.aacrjournals.org/content/10/3/371.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerdiscovery.aacrjournals.org/content/10/3/371.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) RightLink site.